Search
Research
Changes in thymic regulatory T-cell maturation from birth to puberty: Differences in atopic childrenWe report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PATRICIA (PApilloma TRIal against Cancer In young...
Research
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second boosterPICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.
Research
A retrospective population-based cohort study identifying target areas for prevention of acute lower respiratory infections in childrenAcute lower respiratory infections (ALRI) are a major cause of hospitalisation in young children

News & Events
Meningococcal vaccine provides extra protection for bubsIn 2017, a steep rise in cases of meningococcal disease caused by the W strain sparked a wave of concern for parents in Western Australia.

Research
Paediatric Active Enhanced Diseases Surveillance (PAEDS)PAEDS monitors for key vaccine preventable conditions and severe side effects from vaccine in 5 paediatric hospitals in Australia.
Research
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
Preparing for Life: Plasma Proteome Changes and Immune System Development During the First Week of Human LifeNeonates have heightened susceptibility to infections. The biological mechanisms are incompletely understood but thought to be related to age-specific adaptations in immunity due to resource constraints during immune system development and growth. We present here an extended analysis of our proteomics study of peripheral blood-plasma from a study of healthy full-term newborns delivered vaginally, collected at the day of birth and on day of life (DOL) 1, 3, or 7, to cover the first week of life. The plasma proteome was characterized by LC-MS using our established 96-well plate format plasma proteomics platform.
Research
Developmental outcomes following vaccine-proximate febrile seizures in childrenTo compare the developmental and behavioral outcomes of children experiencing an initial vaccine-proximate (VP) febrile seizure (FS) to those having a non-VP-FS (NVP-FS) and controls who have not had a seizure.
Research
Meningococcal B vaccine and meningococcal carriage in adolescents in AustraliaAmong Australian adolescents, the 4CMenB vaccine had no discernible effect on the carriage of disease-causing meningococci, including group B
Research
Impact of Meningococcal ACWY Vaccination Program during 2017-18 Epidemic, Western Australia, AustraliaThe rising incidence of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup W in Western Australia, Australia, presents challenges for prevention. We assessed the effects of a quadrivalent meningococcal vaccination program using 2012-2020 IMD notification data.